More than 356,000 people annually have an out-of-hospital cardiac arrest in the United
States, and most die before reaching the hospital. 1, 2 Prospective, controlled trials have …

In both ischemic and nonischemic heart disease the severity of left ventricular dysfunction
has emerged as the key determinant affecting the decision of which patient should receive …

The implantable cardioverter-defibrillator (ICD) has been shown to be an effective therapy
for the prevention of sudden cardiac death (1), an entity that remains a significant public …

Objectives: The objective of this study was to investigate the feasibility of identifying heart
failure patients who are less likely to benefit from implantable cardioverter-defibrillator (ICD) …

The current guidelines advocate prophylactic implantable cardioverter-defibrillator (ICD) for
all patients with symptomatic heart failure (HF) with low left ventricular ejection fraction …

The implantable cardioverter-defibrillator (ICD) meets class I level of evidence A indication
criteria for patients with narrow QRS width and left ventricular ejection fraction (LVEF)≤ 35 …

Sudden cardiac death (SCD), death that occurs due to cardiac disease within 1 hour from
the onset of symptoms, accounts for as many as 450,000 deaths yearly in the United States …

A post hoc analysis of the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II
showed that patients with high mortality risk score did not benefit from implantable …

Since the invention by Dr Michel Morowski and the first human implantation by Dr Levi
Watkins Jr of an implantable cardioverter defibrillator (ICD) 40 years ago, the life-saving …

Background Implantable cardioverter defibrillators (ICDs) are a proven lifesaving therapy
and their use in the primary prevention setting is supported by Guidelines [1-2]. According to …